Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
Years before semaglutide became a blockbuster drug for Novo Nordisk, the Danish pharma giant had the chance to maintain its patent in Canada but didn’t pay a small fee to do so, according to a recent ...
“Since it is the practice of some large companies to abandon applications or issued patents – sometimes in large numbers – before the first maintenance fee comes due, under the current fee schedule, ...
In-house lawyers explain how outside counsel help them decide which patents to abandon in the face of possible renewal fee hikes In April this year, the USPTO issued a notice of proposed rulemaking ...
Techson continues it AI-powered synthetic patent analytics leadership with the announcement of four major new Limestone|Report upgrades: Maintenance Analytics, Detectability of Infringement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results